Clinical trial
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
NCT00060203 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00060203 |
|---|---|
| Title | Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma |
| Official title | A Phase I/II Study of the Safety and Efficacy of Brostallicin (PNU-166196A) in Adult Patients With Multiple Myeloma That Has Progressed on Prior Chemotherapy |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | brostallicin |
| Enrollment | 3 |
| Start date | Dec 1, 2002 |
| Primary completion | Mar 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | May 7, 2003 |
| Last update posted | Jan 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: